Webinar with Oxford Cannabinoid Technologies plc (OCT)
10 June 2021

This is a third-party event.

Oxford Cannabinoid Technologies is pleased to announce that the Company’s management team will conduct a live presentation to retail investors introducing the company following their recent admission to the London Stock Exchange and presenting the outlook for the year ahead.

Company Description: Oxford Cannabinoid Technologies Holdings plc (“OCT”) is a UK-based next generation cannabis pharmaceutical company focussed on the development cannabinoid-based prescription medicines to target indications in the £42.5bn pain market, with regulatory marketing approval from agencies including the FDA, EMA and MHRA. Established in 2017, OCT aims to become a global leader in developing licensed prescription medicines that target the endocannabinoid system to address significant unmet medical needs. To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Its primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines. Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed four rounds of investment.

Speaker:Neil Mahapatra, Executive Chairman
Bio: Neil Mahapatra is a Co-founder of OCT and serves as Executive Chairman of the Company, having conceptualised the business and directly hired the other Executive Directors. Neil has nearly two decades of experience in business and the investment industry. He began his career in investment banking at Morgan Stanley International plc, in healthcare corporate finance and UK equity capital markets before becoming a private equity executive at J. Rothschild Capital Management Limited, where he led private investments for the family office of Lord Rothschild and RIT Capital Partners plc. Neil is a known and respected leader in the European cannabis industry. Through KCP, Neil sponsored and launched the End our Pain campaign, a prominent campaign that was instrumental in effecting the UK government reforms to medical cannabis legislation in 2018. Outside of business, Neil serves as Chair of the board of a leading global architecture and design non-profit firm, the MASS Design Group, where he also sits on the finance and governance committees. Neil is also a trustee of the Oxford Union Literary and Debating Trust.

Speaker: Dr John Lucas, CEO
Bio: CEO Dr John Lucas brings over 20 years of experience in the pharmaceutical industry. John joined the Group in May 2018. He took on the role of Chief Commercial Officer in August 2018, becoming Chief Executive Officer in January 2021. John began his career in biopharma at Genset S.A. (Paris) and Genset Corporation (San Diego, California) where he served as Vice President, Worldwide Intellectual Property. He also held the position of Vice President, Intellectual Property at Transform Pharmaceuticals Inc. of Lexington Massachusetts, a company specialising in small molecule drug form and formulation and at Metabasis Therapeutics Inc., a biopharmaceutical company in California.

Event details:
Zoom webinar with Oxford Cannabinoid Technologies plc (OCT)
Date: 10 June
Time: 1pm London (GMT)
Speaker: Dr John Lucas (CEO), Neil Mahapatra, (Executive Chairman )

Register in advance for this webinar: https://us02web.zoom.us/webinar/register/1316221058814/WN_RIzq0rv9SQuVHlhGwRcuhQ

Please note that this webinar has been organised by Yellowstone Advisory

Skip to toolbar